Welcome from the ADNI Principal Investigator

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is designed to validate the use of biomarkers including blood tests, tests of cerebrospinal fluid, and MRI/ PET imaging for Alzheimer's disease (AD) clinical trials and diagnosis. AD affects 50% of those over the age of 85 and is the sixth leading cause of death in the US. clinical research.

Among many goals, ADNI is aiming to define the rate of progress of mild cognitive impairment (MCI) and AD, to develop improved methods for clinical trials, and to provide a large database which will improve design of clinical treatment trials. It is anticipated that ADNI will continue in the tradition of providing information and methods that ultimately lead to effective treatment and prevention of AD.

With better knowledge of the earliest stages of the disease, researchers may be able to test potential therapies at earlier stages, when they may have the greatest promise for slowing down progression of this devastating disease. The ADNI study - which is now in its third phase (ADNI, ADNI GO and ADNI 2). ADNI 2 is studying the rate of change of cognition, function, brain structure, function and biomarkers in 200 elderly controls, 400 subjects with mild cognitive impairment, and 200 with AD.

ADNI continues an unprecedented policy of open access to ADNI clinical and imaging data through this website and a parallel website at the Laboratory of Neuroimaging. All data is made public, without any embargo.

Finally, as we begin our overhaul of this website, we welcome any suggestions or comments you may have regarding content. Please direct any content related emails to brainlink@ucsd.edu.

Sincerely,